Skip to content

Study · Animal study (in vivo) · rat and mouse · 2013

6 results

Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases.

Masyuk TV, Radtke BN, Stroope AJ, Banales JM, Gradilone SA, Huang B, Masyuk AI, Hogan MC, Torres VE, Larusso NF

Hepatology (Baltimore, Md.)6 Mar 2013Cited by 83 (Europe PMC)

PMID23172758 (opens in a new tab)PMCIDPMC3616157 (opens in a new tab)DOI10.1002/hep.26140 (opens in a new tab)PepBankPUB-23172758
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In PCK rats and Pkd2(WS25/-) mice, pasireotide inhibited hepatorenal cystogenesis more potently than octreotide within the reported 30%-45% range.

    In plain wordsIn rats and mice, pasireotide inhibited liver and kidney cyst formation more potently than octreotide.

    Peptide
    Pasireotide
    Outcome
    DecreaseHepatorenal cystogenesis
    Study

    rats and micen: not reported in source

    PCK rats and Pkd2(WS25/-) mice
    Comparator
    Octreotide
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that PAS was more potent (by 30%-45%) than OCT in reducing cAMP and cell proliferation, affecting cell cycle distribution, decreasing growth of cultured cysts in vitro, and inhibiting hepatorenal cystogenesis in vivo in PCK rats and Pkd2(WS25/-) mice.
    1 context sentence
    Summary · context
    Here we compare the effects of OCT to pasireotide (PAS; a more potent somatostatin analog with broader receptor specificity) on: (1) cAMP levels, cell cycle, proliferation, and cyst expansion in vitro using cholangiocytes derived from control and PCK rats (a model of autosomal recessive PKD [ARPKD])…
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In PCK rats and Pkd2(WS25/-) mice, octreotide inhibited hepatorenal cystogenesis less potently than pasireotide within the reported 30%-45% range.

    In plain wordsIn rats and mice, octreotide inhibited liver and kidney cyst formation less potently than pasireotide.

    Peptide
    Octreotide
    Outcome
    IncreaseHepatorenal cystogenesis
    Study

    rats and micen: not reported in source

    PCK rats and Pkd2(WS25/-) mice
    Comparator
    Pasireotide
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that PAS was more potent (by 30%-45%) than OCT in reducing cAMP and cell proliferation, affecting cell cycle distribution, decreasing growth of cultured cysts in vitro, and inhibiting hepatorenal cystogenesis in vivo in PCK rats and Pkd2(WS25/-) mice.
    1 context sentence
    Summary · context
    Here we compare the effects of OCT to pasireotide (PAS; a more potent somatostatin analog with broader receptor specificity) on: (1) cAMP levels, cell cycle, proliferation, and cyst expansion in vitro using cholangiocytes derived from control and PCK rats (a model of autosomal recessive PKD [ARPKD])…
  3. 03LabIn vitro (cells)Mechanism

    In cholangiocyte experiments, pasireotide was 30%-45% more potent than octreotide across reported cellular effects on cAMP, proliferation, cell-cycle distribution and cyst growth.

    In plain wordsIn cells, pasireotide was 30%-45% more potent than octreotide across reported effects on cAMP, growth, cyst expansion and cell-cycle distribution.

    Peptide
    Pasireotide
    Outcome
    MixedCombined cellular effects
    Study

    rat and humann: not reported in source

    Cholangiocytes
    Comparator
    Octreotide
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We found that PAS was more potent (by 30%-45%) than OCT in reducing cAMP and cell proliferation, affecting cell cycle distribution, decreasing growth of cultured cysts in vitro, and inhibiting hepatorenal cystogenesis in vivo in PCK rats and Pkd2(WS25/-) mice.
    1 context sentence
    Summary · context
    Here we compare the effects of OCT to pasireotide (PAS; a more potent somatostatin analog with broader receptor specificity) on: (1) cAMP levels, cell cycle, proliferation, and cyst expansion in vitro using cholangiocytes derived from control and PCK rats (a model of autosomal recessive PKD [ARPKD])…
  4. 04LabIn vitro (cells)Mechanism

    In cholangiocyte experiments, pasireotide increased SSTR2 immunoreactivity.

    In plain wordsIn cells, pasireotide increased SSTR2 immunoreactivity.

    Peptide
    Pasireotide
    Outcome
    IncreaseSSTR2 immunoreactivity
    Study

    n: not reported in source

    Cholangiocytes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although both OCT and PAS increased the immunoreactivity of SSTR2, only PAS up-regulated SSTR1; neither drug affected cellular localization of SSTRs.
    1 context sentence
    Summary · context
    Here we compare the effects of OCT to pasireotide (PAS; a more potent somatostatin analog with broader receptor specificity) on: (1) cAMP levels, cell cycle, proliferation, and cyst expansion in vitro using cholangiocytes derived from control and PCK rats (a model of autosomal recessive PKD [ARPKD])…
  5. 05LabIn vitro (cells)Mechanism

    In cholangiocyte experiments, only pasireotide increased SSTR1 expression.

    In plain wordsIn cells, only pasireotide increased SSTR1 expression.

    Peptide
    Pasireotide
    Outcome
    IncreaseSSTR1 expression
    Study

    n: not reported in source

    Cholangiocytes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although both OCT and PAS increased the immunoreactivity of SSTR2, only PAS up-regulated SSTR1; neither drug affected cellular localization of SSTRs.
    1 context sentence
    Summary · context
    Here we compare the effects of OCT to pasireotide (PAS; a more potent somatostatin analog with broader receptor specificity) on: (1) cAMP levels, cell cycle, proliferation, and cyst expansion in vitro using cholangiocytes derived from control and PCK rats (a model of autosomal recessive PKD [ARPKD])…
  6. 06LabIn vitro (cells)Mechanism

    In cholangiocyte experiments, pasireotide did not affect cellular SSTR localization.

    In plain wordsIn cells, pasireotide did not change SSTR location.

    Peptide
    Pasireotide
    Outcome
    No significant changeSSTR cellular localization
    Study

    n: not reported in source

    Cholangiocytes
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although both OCT and PAS increased the immunoreactivity of SSTR2, only PAS up-regulated SSTR1; neither drug affected cellular localization of SSTRs.
    1 context sentence
    Summary · context
    Here we compare the effects of OCT to pasireotide (PAS; a more potent somatostatin analog with broader receptor specificity) on: (1) cAMP levels, cell cycle, proliferation, and cyst expansion in vitro using cholangiocytes derived from control and PCK rats (a model of autosomal recessive PKD [ARPKD])…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.